Non-Small Cell (NSCLC)

S2013: I-CHECKIT ***Only Cohort 2 is open to enrollment***

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

---

A081801

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

---

LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

---

EA5162 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

---